![](https://d2jx2rerrg6sh3.cloudfront.net/image-handler/picture/2018/7/Brain_cancer%2c_3D_illustration_showing_presence_of_tumor_inside_brain_-_Kateryna_Kon_M1_6704c47fefe0477dbe1cd3351402914f-620x480.jpg)
FDA expands orphan drug designation for Roswell Park's brain cancer immunotherapy
The U.S. Food and Drug Administration (FDA) has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center. The supplemental designation awarded to MimiVax Inc. now applies to …